Improvement of Skin Flap Perfusion by Subdermal Injection of Recombinant Human Basic Fibroblast Growth Factor
| Autor: | Imre Bondar, John H. Barker, Konrad Messmer, Eberhard Uhl, Thomas J. Galla, Hans-Anton Lehr |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Male
medicine.medical_specialty Ratón Injections Subcutaneous medicine.medical_treatment Urology Fibroblast growth factor Surgical Flaps Mice Random Allocation chemistry.chemical_compound Internal medicine medicine Animals Fluorescein Skin Mice Hairless Chemotherapy business.industry Growth factor Recombinant Proteins Hairless Perfusion Endocrinology chemistry Fibroblast Growth Factor 2 Surgery business Intravital microscopy |
| Zdroj: | Annals of Plastic Surgery. 32:361-365 |
| ISSN: | 0148-7043 |
| Popis: | The effect of subcutaneously injected recombinant human basic fibroblast growth factor (bFGF) was studied in an arterial skin flap model on the ear of the hairless mouse. Fifty-three male, hairless mice were randomly assigned to 4 groups and pretreated in two different time intervals with different doses of human bFGF. Microvascular perfusion of the skin flaps was determined over a 5-day period by means of intravital microscopy after intravenous injection of the fluorescence marker fluorescein isothiocyanate-dextran (M(r) 150,000). Human bFGF (2,700 ng) injected 6 days before flap creation could not improve perfusion of the flap (n = 10) when compared with controls. However, when applied 18 days before flap creation (n = 13), the same dose resulted in a significant reduction of nonperfused tissue at day 5 after flap creation (12.3% vs 26.8%, p < 0.01). Eighteen-day pretreatment with 1,200 ng (n = 10) and 480 ng (n = 10) had no significant effect on skin flap perfusion. We conclude, therefore, that successful pretreatment with bFGF for prevention of skin flap necrosis is time and dose dependent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|